Publications by authors named "Tami Joseph"

Claim this Profile
A
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
Thomas A Prohaska, Veronica J Alexander, Ewa Karwatowska-Prokopczuk, Joseph Tami, Shuting Xia, Joseph L Witztum

J Clin Lipidol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
Elif A Oral, Abhimanyu Garg, Joseph Tami, Eric A Huang, Louis St L O'Dea, Joseph L Witztum

J Clin Lipidol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Jean-Claude Tardif, Ewa Karwatowska-Prokopczuk, Eric St Amour, Christie M Ballantyne, Michael D Shapiro, Joseph Tami, Joseph L Witztum

Eur Heart J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
PadmaKumar Narayanan, Brian R Curtis, Lijiang Shen, Eugene Schneider, Joseph A Tami, Joseph L Witztum

Nucleic Acid Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapatient study comparing 3D printed bolus versus standard vinyl gel sheet bolus for postmastectomy chest wall radiation therapy.
James L Robar, Kathryn Moran, James Allan, James Clancey, Tami Joseph

Pract Radiat Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Joseph L Witztum

Lancet· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Barry D Kahan, Stanislaw Stepkowski, Murat Kilic, Steven M Katz, Charles T Van Buren, Joseph A Tami

Transplantation· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
K Lea Sewell, Richard S Geary, Brenda F Baker, Josephine M Glover, Timothy G K Mant, Joseph A Tami

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Walter P Maksymowych, Warren D Blackburn, Joseph A Tami, William R Shanahan

J Rheumatol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis